news
Pulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
List view / Grid view
Molecular Targets
article
From lab to clinic: the rise of Radio-DARPins in oncology
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
news
New class of chiral molecules offers strong stability for drug development
Scientists have created a new class of ultra-stable chiral molecules – a discovery that could lead to more precise drug design by preventing potentially harmful molecular “flipping” over time
news
Targeting MAPK and PI3K/mTOR pathways halts ovarian cancer growth
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
news
Mitochondria: melanoma’s hidden vulnerability
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
news
‘Delete-to-recruit’: new gene-editing method targets sickle cell
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
article
The next phase of the multiomics evolution, powered by AI
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
news
How one carbon atom is changing drug development
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
news
Experimental peptide targets glioblastoma’s most resilient cells
An experimental peptide from Virginia Tech may offer a new way to stop glioblastoma from coming back by disrupting the cancer’s treatment-resistant core.
news
Astrocyte protein RTP801 linked to Alzheimer’s cognitive decline
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
news
Targeting PLA2G15 to treat neurometabolic disorders
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
news
Blocking nitrosylation boosts treatment for NRAS melanoma
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
news
PSPC1 knockout slows AML in preclinical models
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
news
UVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
news
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
